Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Oncology
Capecitabine-Associated Loss Of Fingerprints: A Case Report Of A 62-Year-Old Man With Colorectal Cancer Suffering From Capecitabine-Induced Adermatoglyphia, Tasneem Dawood, Muhammad Nauman Zahir, Muhammad Afzal, Yasmin Abdul Rashid
Capecitabine-Associated Loss Of Fingerprints: A Case Report Of A 62-Year-Old Man With Colorectal Cancer Suffering From Capecitabine-Induced Adermatoglyphia, Tasneem Dawood, Muhammad Nauman Zahir, Muhammad Afzal, Yasmin Abdul Rashid
Section of Haematology/Oncology
Background: Capecitabine is a prodrug of 5-fluorouracil (5-FU) and is converted to 5-FU in tumor tissue. Its primary mechanism of action is the suppression of DNA synthesis via inhibition of thymidylate synthetase. It is mostly used for neoadjuvant chemoradiation, adjuvant chemotherapy for colorectal cancer, metastatic breast, and localized and metastatic gastric cancer, among others. Adverse effects of capecitabine include diarrhea, hand-foot syndrome (HFS), pancytopenia, stomatitis, increased bilirubin, nausea, vomiting, and very rarely adermatoglyphia. Dermatoglyphics refers to fingerprints. Adermatoglyphia refers to the loss of fingerprints.
Case review summary: We report the case of a 62-year-old male patient known case of locally …